Ionetix, a mid-Michigan cancer treatment company, receives workforce development funding to train employees in advanced drug development technology.

Diabetes drugs may be doing more than managing blood sugar, they could also shape cancer biology in unexpected ways.

Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded ...

A large, multi-institution study led by a Brown University physician-scientist could have important implications for the development of new classes of cancer therapeutics.

Starton Holdings plans $40M IPO for cancer drug delivery innovations, but weak IP and limited backing make this a potentially ...

SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (including gastroesophageal junction cancer) to SNB-101 (API ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GSK’227, now known as risvutatug rezetecan ...

Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...

Varegacestat, a gamma secretase inhibitor, significantly improved progression-free survival while also meeting all key ...

Cancer drug resistance is the devastating reason that treatments fail and cancers metastasize, spreading to distant sites ...

Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...

Vivesto AB ( ($SE:VIVE) ) has provided an update. Vivesto AB’s extraordinary general meeting on 22 December 2025 approved a major rights issue of ...